These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10217388)

  • 1. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research.
    Minshall ME; Kody MC; Mosbacher F
    Med Care; 1999 Apr; 37(4 Suppl Lilly):AS12-9. PubMed ID: 10217388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
    Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
    Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of epilepsy treatment: a review of the literature.
    Heaney DC; Begley CE
    Epilepsia; 2002; 43 Suppl 4():10-6. PubMed ID: 12059996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology.
    Prendergast MM; Abramovits W; Boguniewicz M; Lebwohl M; Tokar M; Tong KB
    J Invest Dermatol; 2004 Sep; 123(3):452-4. PubMed ID: 15304081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes measurement. The key to the appropriate use of pharmaceuticals.
    Grey RR; Townsend RJ; Sanders CA
    Int J Technol Assess Health Care; 1995; 11(3):472-84. PubMed ID: 7591548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for pharmacoeconomic and outcomes research fellowship training programs: joint guidelines from the american college of clinical pharmacy and the international society of pharmacoeconomics and outcomes research.
    Kane-Gill S; Reddy P; Gupta SR; Bakst AW
    Pharmacotherapy; 2008 Dec; 28(12):1552. PubMed ID: 19025439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
    Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
    Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
    [No Abstract]   [Full Text] [Related]  

  • 13. The Hanover Consensus: helpful for German decision-makers?
    Kolominsky-Rabas PL; Caro JJ
    Value Health; 2008; 11(4):545-6; discussion 547-8. PubMed ID: 18489522
    [No Abstract]   [Full Text] [Related]  

  • 14. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].
    Med Klin (Munich); 2000 Jan; 95(1):52-5. PubMed ID: 10668346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference.
    Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):305-7. PubMed ID: 19670989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical issues in intervention outcomes.
    Bruhn JG
    Fam Community Health; 2001 Jan; 23(4):24-35. PubMed ID: 11401621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action.
    Al-Jazairi AS; Al-Qadheeb NS; Ajlan A
    Ann Saudi Med; 2011; 31(4):335-41. PubMed ID: 21808106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open data on industry payments to healthcare providers reveal potential hidden costs to the public.
    Mejia J; Mejia A; Pestilli F
    Nat Commun; 2019 Sep; 10(1):4314. PubMed ID: 31541096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.